Growth Hormone Treatment of Early Growth Failure in Toddlers with Turner Syndrome: A Randomized, Controlled, Multicenter Trial

Davenport, Marsha L.; Crowe, Brenda; Travers, Sharon H.; Rubin, Karen; Ross, Judith L.; Fechner, Patricia Y.; Gunther, Daniel F.; Liu, Chunhua; Geffner, Mitchell E.; Thrailkill, Kathryn M.; Huseman, Carol A.; Zagar, Anthony; Quigley, Charmian A.

doi:10.1210/jc.2006-2874

Cited by 135 publications

(84 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results of this study confirm that most girls with TS can exhibit an important height improvement during the first years of GH therapy, as also recently reported by other authors in early treated patients (17,18,19). By contrast, long-term auxological results of treatment may not be so positive, as is suggested by our findings.…”

Section: Discussionsupporting

confidence: 92%

“…Age at initiation and duration of GH therapy is known to be an important factor in determining GH effectiveness and, therefore, such treatment in TS should be started as soon as growth failure is observed (17). Early onset of GH therapy not only allows longer duration of treatment, but utilizes a window of higher responsiveness in these girls (18).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Adult height in girls with Turner syndrome treated from before 6 years of age with a fixed per kilogram GH dose

Wasniewska¹,

Aversa

Mazzanti

et al. 2013

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: To evaluate adult height (AH) in 25 girls with Turner syndrome (TS) who were treated from before 6 years of age for 10.0G1.7 years with a fixed GH dose of 0.33 mg/kg per week. Patients and design: After a 6-month pretreatment assessment all patients were measured 6-monthly under therapy to assess height SDS (H-SDS) and height velocity (HV) until AH achievement. Results: Following initial acceleration, HV declined after the first 4 years of therapy. At the end of the sixth year of therapy, H-SDS gain was 1.9G1.1. Thereafter, H-SDS gain from baseline decreased, becoming 0.9G0.9 SDS at AH achievement. Bone maturation velocity did not significantly change throughout the prepubertal period. According to Lyon standards for TS, mean AH SDS was significantly higher than pretreatment H-SDS (P!0.0001), with a mean H-SDS change of 0.9G0.9. However, the prevalence of patients with AH !K2 SDS (according to Sempé standards) was close to those recorded at the start of therapy (16/25 vs 18/25). No significant differences in terms of AH were found between patients with either X monosomy or X-chromosomal abnormalities and between girls with either spontaneous or induced puberty. Conclusions: We infer that the therapeutic regimen adopted in this prospective study is sufficient to induce a significant growth acceleration during the first year, but the response waned after 6 years of treatment.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Adult height in girls with Turner syndrome treated from before 6 years of age with a fixed per kilogram GH dose

Wasniewska¹,

Aversa

Mazzanti

et al. 2013

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Based on data focusing on growth plate senescence and hormonal impact it becomes clear that the enhanced growth responsiveness of GH at the young age is unlikely to be mediated by IGF-1, but appears to reside within the growth plate itself [68][69][70]. Any disorder at the level of growth plate is bound to result in short stature and may present with different growth responsiveness and, therefore, a given GH therapy has to be correspondingly personalized [71]. In addition, for these non-GHD conditions, GH is used in a pharmacological manner rather than as physiologic replacement, and, therefore, the GH dose is rather high in order to improve height velocity and increase final height [72].…”

Section: Growth Responsiveness To Gh Therapy the Impact Of The Growtmentioning

confidence: 99%

Biological Determinants of Responsiveness to Growth Hormone: Pharmacogenomics and Personalized Medicine

Mullis¹

2010

Current Indications for Growth Hormone Therapy

View full text Add to dashboard Cite

It is becoming most clear that many genes are involved in controlling the regulation of growth. Ultimately however, at the level of growth hormone (GH), the relevant question may be not whether a patient is GH-deficient, but whether he is GH-responsive. As these disturbances can be divided into two gross categories, namely alterations causing subnormal GH secretion and/or those presenting with subnormal GH sensitivity/responsiveness, the main aim of this review is to focus on genes involved in growth regulation leading to short stature caused by an alteration of GH insensitivity/GH responsiveness; in other words, clinical circumstances where individually adapted GH replacement therapy may help to increase height velocity and eventually final height.

show abstract

“…O tratamento com GHr, além do impacto no crescimento somático, influencia de maneira positiva o comportamento psicossocial e a qualidade de vida das pacientes, sobretudo quando associado, no tempo adequado, à terapia estrogênica (22,23).…”

Section: Tratamento Com Hormônio De Crescimento Recombinante (Ghr)unclassified

O hormônio de crescimento na síndrome de Turner: dados e reflexões

Guedes

Bianco

Callou

et al. 2008

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

A baixa estatura é a principal característica na síndrome de Turner (ST). O agravo estatural na ST é precoce e torna-se mais evidente na puberdade. A haploinsuficiência do gene SHOX tem sido implicada como principal fator na definição da estatura de mulheres, no entanto, ainda que a maioria das pacientes não tenha deficiência do hormônio de crescimento, a terapia com GHr melhora a altura final. Recentemente, tem-se chamado a atenção para a associação entre GH e câncer. O risco de câncer nessas pacientes está associado à presença de fragmentos do cromossomo Y que pode levar ao desenvolvimento de gonadoblastoma. Dessa forma, a administração de GHr na ST deve ser feita com cautela. A investigação de seqüências do cromossomo Y deve ser realizada, bem como a gonadectomia profilática nos casos positivos, conferindo maior segurança ao tratamento.

show abstract

Growth Hormone Treatment of Early Growth Failure in Toddlers with Turner Syndrome: A Randomized, Controlled, Multicenter Trial

Abstract: Early GH treatment can correct growth failure and normalize height in infants and toddlers with TS.

Cited by 135 publications

References 46 publications

Adult height in girls with Turner syndrome treated from before 6 years of age with a fixed per kilogram GH dose

Adult height in girls with Turner syndrome treated from before 6 years of age with a fixed per kilogram GH dose

Biological Determinants of Responsiveness to Growth Hormone: Pharmacogenomics and Personalized Medicine

O hormônio de crescimento na síndrome de Turner: dados e reflexões

Contact Info

Product

Resources

About